Circulating sclerostin in children and young adults with heritable bone disorders

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages

  Palomo, Telma ^a   Glorieux, Francis H ^a   Rauch, Frank ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; SCLEROSTIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE MASS; BONE TURNOVER; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; X LINKED HYPOPHOSPHATEMIC RICKETS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CHILD; CHILD, PRESCHOOL; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; GENETIC MARKERS; HUMANS; INFANT; MALE; OSTEOGENESIS IMPERFECTA;

EID: 84899899676     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3852     Document Type: Article

References (32)

1. Ke HZ Richards WG Li X Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases Endocr Rev. 2012 33 747-783.
2. Baron R, Kneissel M. WNT sig naling in bone homeostasis and disease: from human mutations to treatments. NatMed. 2013;19:179-192.
3. Drake MT, Srinivasan B, M ödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5056-5062.
4. Roforth MM, Fujita K, McGregor UI, et al. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone. 2014;59:1-6.
5. Frings-Meuthen P, Boehme G, Liphardt AM, Baecker N, Heer M, Rittweger J. Sclerostin andDKK1levels during 14 and 21 days of bed rest in healthy young men. J Musculoskelet Neuronal Interact. 2013; 13:45-52.
6. Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH. Decreased serum sclerostin levels in pat ients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2012;23:1789-1797.
7. Fischer DC, Mischek A, Wolf S, et al. Paediatric reference values for th e C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem. 2012;49:546-553.
8. Kirmani S, Am in S, McCready LK, et al. Sclerostin levels during growth in children. Osteoporos Int. 2012;23:1123-1130.
9. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26:1381-1388.
10. Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calc itriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med. 1980;303:1023-1031.
11. Cheung M, Roschger P, Klaushofer K, et al. Cortical and trabecular bone density in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2013;98:E954-E961.
12. Forlino A, Cabral WA, Barnes AM, Marini JC.Newperspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7:540-557.
13. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363: 1377-1385.
14. Owen C, Chen F, Flenniken AM, et al. A novel Phex mutation in a new mouse model of hypophosphatemic rickets. J Cell Biochem. 2012;113:2432-2441.
15. Liu S, Tang W, Fa ng J, et al. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol. 2009;23:1505-1518.
16. Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011;26:1425-1436.
17. Sinder BP, Eddy MM, Ominsky MS, et al. Sclerostin antibody improves skeletal parameters in a Brtl/-mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28:73-80.
18. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Ce nters for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109:45-60.
19. Mödder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373-379.
20. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre-and postmenopausal women. J Bone Miner Res. 2011;26:2812-2822.
21. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab. 2013;98:3873-3883.
22. Salle BL, Braillon P, Glorieux FH, Brunet J, Cavero E, Meunier PJ. Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr. 1992;81:953-958.
23. Southard RN Morris JD Mahan JD et al. Bone mass in healthy children: measurement with quantitative DXA Radiology. 1991 179 735-738
24. Glastre C, Braillon P, Davi d L, Cochat P, Meunier PJ, Delmas PD. Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab. 1990;70:1330-1333.
25. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010;25:178-189.
26. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmeno pausal women: The OFELY study. Osteoporos Int. 2013; 24:489-494.
27. Mullen CA, Haugh MG, Schaffler MB, Majeska RJ, McNamara LM. Osteocyte differentiation is regulated by extracellular matri x stiffness and intercellular separation. J Mech Behav Biomed Mater. 2013;28C:183-194.
28. Frost HM. Some observations on bone mineral in a case of vitamin D resistant rickets. Henry Ford Hosp Med Bull. 1958;6:300-310.
29. Marie PJ, Glorieux FH. Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcif Tissue Int. 1983;35:443-448.
30. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26:581-589.
31. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporos is is associated with a dose dependent increase in serum sclerostin. Bone. 2012;50:739-742.
32. Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A. Zoledronic acid acu tely increases sclerostin serum levels in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2013;98:1911-1915.